Haleon plc 6-K, filed May 19, 2025
Haleon plc (HLN)
6-K
2025-05-19
For: 2025-05-19
View Original
Added on
July 04, 2026
About this 6-K
Haleon plc filed this 6-K on May 19, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
|
|
|
99.1
|
19 May
2025 - “Transaction in Own
Shares”
|
99.1
Haleon plc: Transaction in own shares
19 May 2025: Haleon plc (the "Company" or
"Haleon") today announces the purchase of the following number of
ordinary shares of £0.01 each in the Company (the "Shares")
for cancellation under its share buyback programme announced on 28
March 2025 (the "Buyback Programme").
|
Date of purchase:
|
16 May 2025
|
|
Number of Shares purchased:
|
825,666
|
|
Highest price paid per share (p):
|
406.30
|
|
Lowest price paid per share (p):
|
401.70
|
|
Volume weighted average price paid per share (p):
|
404.03
|
Following the settlement of the above, the Company's registered
share capital is 9,012,587,392 ordinary shares of £0.01 each,
of which 4,080,205 are held as treasury shares. Therefore, the
number of ordinary shares with voting rights is 9,008,507,187 and
this figure may be used by shareholders to determine if they are
required to notify their interest, or a change to their interest,
in Haleon under the FCA's Disclosure Guidance and Transparency
Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014
as it applies in the UK
(the Market Abuse Regulation), a full breakdown of the individual
trades is available at the link below:
This announcement does not constitute, or form part of, an offer or
any solicitation of an offer for securities in any
jurisdiction.
This announcement and individual trade breakdown will also be
available on the Company's website at: www.haleon.com/investors.
Enquiries
|
Investors
|
|
Media
|
|
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Emma White
|
+44 7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date: May 19,
2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|